ARCHIVES

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

Patient Accrual Up More Than 20% This Year Despite Lack Of Significant New Money For Group

November 18, 1988

Harvard’s DePinho Becomes Finalist at MD Anderson

May 20, 2011

Cause Of Allergic Reaction To Cetuximab Found

March 28, 2008

Patients Sue Milken, Cancer Centers, Over Prostate Cancer Remedy PC-Spes

February 20, 2004

Ruckdeschel To Direct Nevada Cancer Institute

February 6, 2009

Letter: Headline Criticized On Letter About Consortium

June 21, 1996